Tilray Brands Not Dependent on Single Market, CEO Highlights Multiple Growth Engines

10/8/2026
Impact: 70
Healthcare

Tilray Brands Inc. reported a first-quarter 2027 adjusted loss of 2 cents per share, surpassing the consensus loss of 20 cents. Sales increased by 23% year-over-year to $257.147 million, though this fell short of Wall Street's estimate of $267.813 million. The company reaffirmed its fiscal year 2027 adjusted EBITDA guidance of $68 million to $75 million, indicating double-digit growth compared to fiscal year 2026. In premarket trading, Tilray's shares fell 2.01% to $3.64, approaching its 52-week low of $3.54.

AI summary, not financial advice

Share: